TREACE MEDICAL CONCEPTS, INC. 8-K

What Happened

• Treace Medical Concepts, Inc. (TMCI) filed an 8‑K on April 9, 2026 announcing preliminary, unaudited results for Q1 2026 and the departure of Chief Commercial Officer Gaetano M. Guglielmino effective April 8, 2026.
• The company estimated Q1 revenue of $47.0M–$47.2M and cash, cash equivalents and marketable securities of about $51.9M as of March 31, 2026. TMCI updated its full‑year 2026 revenue guidance to $202M–$212M (previously $200M–$212M). The preliminary figures are subject to closing procedures and final audit.

Key Details

• CCO departure: Gaetano M. Guglielmino left effective April 8, 2026; the company will not refill the CCO role and the Senior VP, Sales will report directly to CEO John T. Treace. The departure is not due to any dispute or disagreement.
• Consulting agreement: Effective April 9, 2026, Guglielmino will consult through Jan 31, 2027 for $36,666.67 per month, COBRA premium payments, a pro‑rated 2026 target bonus, apartment rent payment until lease assignment, and continued vesting of existing equity awards; he also signed a release and confirmed confidentiality/noncompete obligations.
• Financials: Preliminary Q1 revenue $47.0M–$47.2M; cash & equivalents ~ $51.9M (up ~$3.5M vs. $48.4M at 12/31/2025). Updated 2026 revenue guidance raised at the low end to $202M–$212M, reflecting continued case growth offset by product/price mix headwinds in the bunion portfolio.

Why It Matters

• Revenue and cash: The preliminary Q1 revenue and higher cash balance signal continued commercial activity and liquidity heading into 2026, but figures are unaudited and may change. The raised low end of full‑year guidance suggests management expects slightly stronger topline performance than previously forecast.
• Leadership change: Losing the CCO could affect commercial strategy execution, but the company is reallocating responsibilities to current staff and has a consulting transition arrangement to mitigate disruption. Investors should watch finalized Q1 results, commentary on product mix impacts, and any further commercial leadership moves.